RESUMEN
OBJECTIVE: To explore the efficacy, mechanism and safety of silibinin combined with Ruangan pills (a Chinese herbal preparation) in the treatment of schistosomiasis liver fibrosis. METHODS: A total of 200 patients with schistosomiasis liver fibrosis were randomly divided into a control group and a treatment group, and 100 patients in each group were respectively administered with oral silibinin alone and oral silibinin combined with Ruangan pills, respectively. The curative effects in the two groups were evaluated in 3 months, 6 months, 9 months and 12 months respectively. RESULTS: The common five clinical symptoms of schistosomiasis liver fibrosis patients significantly relieved in the treatment group 12 months after the therapy, and the total efficiency reached more than 75%, which were significantly higher than that in the control group. In the treatment group and the control group, there was no improvement in the liver B ultrasonic classification 3 months and 6 months after the therapy (P > 0.05); however, in 9 months and 12 months, the liver B ultrasonic classification in the treatment group was better than that in the control group (P < 0.05, P < 0.01, respectively). For the four serum indexes of liver fibrosis, there was no significant differences between the two groups in 3 months, however, in 6 months, 9 months, and 12 months, there was a significant improvement in the treatment group compared with the control group. There were no obviously adverse effects in two groups. CONCLUSION: Silibinin combined with Ruangan pills has a better curative effect in the treatment of schistosomiasis liver fibrosis.
